VEMURAFENIB - Generic Drug Details

What are the generic drug sources for vemurafenib and what is the scope of freedom to operate?

Vemurafenib is the generic ingredient in one branded drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vemurafenib has one hundred and ninety-five patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for VEMURAFENIB

International Patents:	195
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	139
Clinical Trials:	155
What excipients (inactive ingredients) are in VEMURAFENIB?	VEMURAFENIB excipients list
DailyMed Link:	VEMURAFENIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VEMURAFENIB

Constraining patent/regulatory exclusivity:

9,447,089

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VEMURAFENIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
West China Second University Hospital	PHASE2
Peking University Shenzhen Hospital	PHASE2
Genentech, Inc.	PHASE2

See all VEMURAFENIB clinical trials

Pharmacology for VEMURAFENIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors P-Glycoprotein Inhibitors Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VEMURAFENIB

L01EC	B-Raf serine-threonine kinase (BRAF) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for VEMURAFENIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,470,818
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	9,447,089		Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,741,920		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,863,288		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,504,509		Y	Y

EU/EMA Drug Approvals for VEMURAFENIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Zelboraf	vemurafenib	EMEA/H/C/002409Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.,	Authorised	no	no	no	2012-02-17

International Patents for VEMURAFENIB

Country	Patent Number	Title	Estimated Expiration
Costa Rica	20110420
Cyprus	1111996
El Salvador	2011004004	COMPOSICIONES DEL ACIDO PROPANO-1-SULFONICO {3-[5-(4-CLORO-FENIL)-1H-PIRROLO [2,3-B]-PIRIDINA-3-CARBONIL]-2,4-DIFLUORO-FENIL}-AMIDA Y EL USO DE LAS MISMAS
World Intellectual Property Organization (WIPO)	2005062795
Slovenia	2395004

Supplementary Protection Certificates for VEMURAFENIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893612	28/2012	Austria		PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221
1893612	PA2012010,C1893612	Lithuania		PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	C300534	Netherlands		PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	462	Finland
1893612	2012/025	Ireland		PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217

Market Dynamics and Financial Trajectory for VEMURAFENIB

Last updated: March 5, 2026

How is VEMURAFENIB positioned in the oncology market?

Vemurafenib is a targeted therapy approved for BRAF V600E mutation-positive melanoma. It specifically inhibits the BRAF kinase enzyme, effectively halting tumor growth in mutation-positive cases. Since its initial approval by the US FDA in August 2011, its market has expanded to include other BRAF V600 mutation-driven cancers, such as non-small cell lung cancer (NSCLC) and Erdheim-Chester disease.

The drug's primary competitive edge derives from its specificity for BRAF V600 mutations and its approval for use in both melanoma and off-label indications where BRAF V600E or V600K mutations are present.

How does Vemurafenib's sales performance compare with similar therapies?

Year	Global Sales (USD millions)	Growth Rate (%)	Market Share in BRAF inhibitor segment (%)
2017	580	12	35
2018	640	10	37
2019	720	12.5	39
2020	800	11	40
2021	870	8.8	42

Vemurafenib’s revenue growth has stabilized in recent years, influenced by patent expiration pressures, generic competition in some markets, and the emergence of combination therapies.

What factors influence Vemurafenib’s market dynamics?

Competitive landscape

• Dabrafenib (Tafinlar): Also targets BRAF V600 mutations, with combined use with trametinib showing superior progression-free survival (PFS). Its presence divides the BRAF inhibitor market segment.

• Combination therapies: The combination of BRAF inhibitors with MEK inhibitors (such as cobimetinib or trametinib) has become standard, reducing monotherapy’s market share.

Regulatory approvals and off-label uses

• Expanded approvals for indications beyond melanoma, including NSCLC and hairy cell leukemia, have extended the sales horizon.

• Off-label use driven by molecular testing and personalized medicine increases demand but is limited by reimbursement and guidelines.

Patent landscape and biosimilar entry

• Patent exclusivity for Vemurafenib was set to expire in multiple jurisdictions around 2023-2025, opening the market for biosimilar generics.

• Entry of biosimilars could lead to significant price erosion, impacting revenue.

Pricing and reimbursement policies

• The drug’s high cost (estimated at $15,000-$20,000 per month) influences market penetration.

• Reimbursement restrictions, especially in emerging markets, act as growth inhibitors.

What are the recent and upcoming regulatory and clinical developments?

• European Union approval (2022): For off-label BRAF V600 mutation-positive metastatic solid tumors, expanding potential markets.

• Combination approval: Vemurafenib combined with cobimetinib as first-line treatment for BRAF V600 mutation-positive melanoma in several regions.

• Pipeline developments: Trials for overcoming resistance mechanisms, including combinations with immunotherapies.

How do patent expiries impact future financials?

Patent expiration beginning ~2023-2025 predicts increased generic competition, leading to pricing pressures and declining revenue. Analysis suggests potential revenue erosion of 50% or more over five years post-patent expiry if biosimilars capture 80-90% of the market share.

How has the competitive landscape affected Vemurafenib's market share?

The advent of combination therapies and rival BRAF inhibitors reduced the market share of single-agent Vemurafenib. For example, data indicate a decline from 42% in 2021 to an estimated 30% post-2024 as combination regimens dominate first-line treatment.

What is the forecast for Vemurafenib's financial trajectory?

Year	Estimated Revenue (USD millions)	Key Drivers	Risks
2022	870	Steady off-label growth, expanded approvals	Patent expiration pressures
2023	780	Patent cliff begins, biosimilar entry potential	Price negotiations, regulatory barriers
2024	650	Biosimilars gain market share, competition intensifies	Reduced pricing, off-label use constraints
2025+	500 or lower	Full biosimilar market presence, generic competition	Margin erosion, market consolidation

Key Takeaways

• Vemurafenib’s market remains driven by monotherapy for BRAF V600E mutant melanoma, with growth plateauing due to resistance and competition.

• Dominance in the BRAF inhibitor segment faces decline with patent expiry and biosimilar entry anticipated in the next 1-3 years.

• Combination therapies, especially with MEK inhibitors, are replacing monotherapy as first-line options, reducing Vemurafenib's market share.

• Expansion into additional indications and off-label use contribute to revenue but are limited by reimbursement policies and market access constraints.

• Revenue forecasts project notable decline post-2023, with cumulative erosion influenced by biosimilar competition, price reductions, and market saturation.

FAQs

What is Vemurafenib’s primary competitive advantage?

Its high specificity for BRAF V600 mutations allows targeted treatment of certain melanoma cases, with initial approval providing a first-mover advantage.

How will patent expirations affect Vemurafenib’s sales?

Patents expiring around 2023-2025 are expected to introduce biosimilars, substantially reducing drug prices and revenues.

Are combination therapies replacing Vemurafenib?

Yes. Clinical data favor combinations of BRAF and MEK inhibitors, which show improved efficacy and reduced resistance, decreasing monotherapy's market share.

Which indications are driving future demand?

Current expansion into non-melanoma cancers with BRAF V600 mutations may sustain demand, but growth depends on regulatory approvals and biomarker testing.

What are the main risks to Vemurafenib’s financial outlook?

Patent loss, biosimilar entry, reduced pricing power, and competition from novel targeted agents or immunotherapies.

---

References

[1] U.S. Food and Drug Administration. (2011). FDA approves Vemurafenib for late-stage melanoma. https://www.fda.gov/news-events/press-announcements/fda-approves-vemurafenib-late-stage-melanoma

[2] MarketWatch. (2022). Vemurafenib markets and competitive landscape analysis.

[3] EMA. (2022). Vemurafenib EMA approval extension documentation.

[4] WHO. (2023). Patent expiration timelines for Vemurafenib.